伊克力西斯 EXEL 深 沪
等待开盘 07-26 09:30:00 美东时间
45.60
+0.810
+1.81%
华盛通- 最 高45.72
- 今 开45.21
- 成交量 357.30万股
- 最 低 44.83
- 昨 收 44.79
- 总市值 124.49亿
- 52周最高 49.62
- 市盈率 静 25.91
- 换手率 1.31%
- 52周最低 23.21
- 委 比 -90.01%
- 总股本 2.73亿
- 历史最高 49.62
- 量 比 1.72
- 振 幅 1.99%
- 历史最低 1.26
- 每 手 1
- 风险率 6.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Uncovering Potential: Exelixis's Earnings Preview
Exelixis (NASDAQ:EXEL) is gearing up to announce its quarterly earnings on Mond...
07-25 23:01
Exelixis Announces EU Approval Of CABOMETYX As First Systemic Therapy For Previously Treated Neuroendocrine Tumors
– Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo –– CABOMETYX is the
07-25 05:05
Morgan Stanley Maintains Overweight on Exelixis, Raises Price Target to $48
Morgan Stanley analyst Jefferson Harralson maintains Exelixis (NASDAQ:EXEL) with a Overweight and raises the price target from $47 to $48.
07-22 20:46
Top rated and bottom rated stocks according to 3 key drivers of performance – UBS
UBS analysts listed top and bottom-ranked stocks based on a key set of drivers for equities, they named REVS. UBS’s REVS framework consists of elements that are key drivers for equity performance, inc...
07-11 23:33
美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
Assessing Exelixis: Insights From 12 Financial Analysts
In the last three months, 12 analysts have published ratings on Exelixis (NASDA...
07-11 05:00
Barclays Maintains Equal-Weight on Exelixis, Raises Price Target to $40
Barclays analyst Peter Lawson maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $29 to $40.
07-11 00:32
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs c...
07-08 22:25
Peering Into Exelixis's Recent Short Interest
Exelixis's (NYSE:EXEL) short percent of float has risen 9.62% since its last re...
07-05 01:00
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
